Zomedica director Christopher MacLeod acquires $8,437 in stock

ANN ARBOR, MI—Christopher MacLeod, a director at Zomedica Corp. (NYSEAMERICAN:ZOM), recently purchased 143,000 shares of the company’s common stock, amounting to a total value of $8,437. The transaction, executed on March 17, 2025, was conducted at a price of $0.059 per share. Following this acquisition, MacLeod’s direct ownership in the company stands at 143,000 shares. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company maintains a strong balance sheet with cash exceeding debt. Zomedica, headquartered in Ann Arbor, Michigan, is a player in the pharmaceutical preparations sector. The company reported revenue of $1.2 billion in the last twelve months, with a robust gross profit margin of 88%. InvestingPro analysis suggests the stock is currently undervalued, with 12 additional exclusive insights available to subscribers through their comprehensive Pro Research Report.

In other recent news, Zomedica Pharmaceuticals (NYSE:ZOM) Corp reported its fourth-quarter 2024 earnings, showcasing a revenue of $7.9 million, which signifies an 8% increase compared to the previous year. Despite recording a net loss of $7.2 million, the company maintained strong gross margins and a solid cash position with $71.4 million in liquidity. The full-year revenue for 2024 reached a record $27.3 million, reflecting consistent growth across its portfolio. The company’s strategic focus on the veterinary market continues to support its expansion efforts, particularly in the equine segment. Additionally, Zomedica has been actively pursuing international expansion, having received CE marking for multiple products, allowing sales in the EU and other markets. In other developments, Zomedica transitioned to the OTCQB Venture Market following its delisting from the NYSE American Exchange, which was due to not meeting the minimum listing standards. The company remains committed to addressing its share price and exploring options to return to a major exchange. Lastly, Zomedica recently signed a distribution agreement with Crestlon for the Betagel hemostatic gel product line, expanding its portfolio into new veterinary care areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.